We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Research published in the NEJM suggests two doses of Pfizer/BioNTech or AstraZeneca's COVID-19 vaccines are nearly as effective against the highly transmissible Delta variant as they are against the previously dominant Alpha variant.